Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Drug Regulators Extend Rare Fast-track Approval For J&J Drug

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - In an extremely rare case of fast-track approval for a special class of medicines, Chinese drug regulators have given the green light for a Johnson & Johnson drug to be launched nationwide before the completion of clinical trials inside China

You may also be interested in...



San Francisco-based FibroGen Gets SFDA Nod Through Green Channel Procedure

HONG KONG - San Francisco-based FibroGen announced that Chinese regulators approved the start of clinical trials of novel therapy FG-4592 for anemia associated with chronic kidney disease. The approval was expedited through China's two-year-old special approval procedure, or "green channel.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC072675

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel